BRAF mutation testing is one of the best examples how modern genetic testing may help to effectively use targeted therapies in cancer patients. Since many different genetic techniques are employed to assess BRAF mutation status with no available comparison of their sensitivity and usefulness for different types of samples, we decided to evaluate our own PCR-based assay employing the amplification refractory mutation system (ARMS-PCR) to detect the most common hotspot mutation c. T1799A (p. V600E) by comparing it with two qPCR based assays: a commercially available test with hybridizing probes (TIB MOLBIOL) and high resolution melting (HRM). Positive results were verified with Sanger sequencing. DNA from two cancer cell lines with known mutation status and from tissue samples from melanoma and gastric cancer was used. ARMS-PCR was the most sensitive method with the level of detection of the mutant allele at 2%. Similar sensitivity was observed for the qPCRbased commercial test employing hybridizing probes; however, this test cannot exclude negative results from poor or low quality samples. Another qPCR-based method, HRM, had lower sensitivity with the detection level of approximately 20%. An additional drawback of HRM methodology was the inability to distinguish between wild type and mutant homozygotes in a straightforward assay, probably due to the character of this particular mutation (T>A). Sanger sequencing had the sensitivity of the detection of mutant allele similar to HRM, approx. 20%. In conclusion, simple ARMS-PCR may be considered the method of choice for rapid, cost-effective screening for BRAF p. V600E mutation.
INTRODUCTION
In recent years, the BRAF gene encoding a cytoplasmic serine/threonine kinase, has become a highlight of targeted treatment concept in cancer therapy. Initial discovery of BRAF mutations in a variety of cancers (Davies et al., 2002) , followed by research on the role of BRAF in carcinogenesis have led to the successful introduction of its inhibitor, vemurafenib (formerly PLX4032) , marking a significant progress in the treatment of advanced melanoma, and opening new therapeutic possibilities in other cancers (Kopetz S, 2010) .
BRAF kinase is one of the major components of the RAS-RAF-MEK-ERK mitogen-activated protein kinase signalling pathway, which has a crucial impact on cell proliferation (Robinson & Cobb, 1997) , therefore the discovery of BRAF activating mutations quickly led to its recognition as an oncogene . In contrast to wild-type BRAF, physiologically activated by RAS protein, constitutively active BRAF mutants phosphorylate their downstream targets in a RAS-independent manner, which results in mitogen-independent signalling (Wan et al., 2004) . While it is currently accepted that oncogenic BRAF is incapable of driving tumorigenesis alone (Michaloglou et al., 2005) and mutations are frequently observed in benign skin lesions (Pollock et al., 2003) , tumors harbouring BRAF mutation are highly dependent on its effects (Hingorani et al., 2003; Solit et al., 2006) . This is reflected in the significant prevalence of BRAF variants in many types of cancer. Mutations can be found at high frequencies in melanoma (40%-68% of samples) (Kumar et al., 2003; Davison et al., 2005) , papillary thyroid carcinoma (36-69%) (Cohen et al., 2003; Trovisco et al., 2004) , nervous system tumors (up to 66%) (Schindler et al., 2011) and they are present virtually in every case of hairy-cell leukemia (Tiacci et al., 2011; Arcaini et al., 2012) . Furthermore, BRAF mutations are detected at lower frequencies in other cancers, such as multiple myeloma (4%) , colorectal (7.2-22% of samples) (Wang et al., 2003; Saridaki et al., 2011) and adrenocortical carcinomas (5.7%) (Kotoula et al., 2009) as well as lung adenocarcinomas (1.6-2%) (Naoki et al., 2002; Schmid et al., 2009) . Apart from those cancers, BRAF seems to be implicated in development of Langerhans' cell histiocytosis, where its mutations are present in 57% of cases (Badalian-Very et al., 2010) , and cardiofaciocutaneous syndrome, where 78% of individuals have germline BRAF mutations (Rodriguez-Viciana et al., 2006) .
The characteristic feature of BRAF variants is their restricted diversity. Generally, exons 11 and 15 are most frequently being affected by various substitutions (Davies et al., 2002) , but an overwhelming majority of mutations can be found in codon 600 in exon 15 and one of them, the c. T1799A substitution resulting in valine to glutamic acid change (p. V600E), accounts for 80-100% of mutations (Kumar et al., 2003; Houben et al., 2004; Libra et al., 2005; Tiacci et al., 2011) .
Ubiquity of BRAF mutations, along with their uniformity and availability of BRAF inhibitors implies a promising perspective for targeted therapy. However, BRAF mutation status can also serve as a predictive or prognostic factor, as in colorectal cancer. Clinical response of the anti-EGFR treatment in colorectal cancer with anti-EGFR antibodies (e.g. cetuximab, panitumumab) depends on preserved wild-type status of BRAF (as well as KRAS) (Di Nicolantonio et al., 2008) . In this tumor, BRAF alterations were also found to correlate with worse survival, making BRAF mutation status a strong prognostic factor (Di Nicolantonio et al., 2008; Yokota et al., 2011) .
Therefore, there is a growing need to screen for the status of BRAF mutation in different tumors and although there are several different methods available there are only few reports comparing some of the methods (Yancovitz et al., 2007; Ellison et al., 2010) . Moreover, there is a need for a cheap and sensitive PCR-based assay to rapidly and reliably check the status of BRAF.
Here we decided to detect hotspot c. T1799A (p. V600E) mutation employing three different PCRbased screening methods, i.e. Amplification Refractory Mutation System PCR (ARMS) (Newton et al., 1989) , High Resolution Melting (HRM) (Wittwer et al., 2003) and commercially available, BRAF T1799A (p. V600E) mutation-targeted qPCR with hybridizing probes. Since Sanger sequencing is commonly used to verify results obtained with different methods, we also applied this technique to confirm the results of PCR-based methods and to compare their sensitivity and specificity.
MATERIALS AND METHODS
Cell lines and patient samples. Optimization and comparison of different detection methods were performed using two human cancer cell lines: A375 melanoma cell line harbouring homozygous BRAF c. T1799A (p. V600E) mutation, and MIA PaCa-2 pancreatic cancer cell line homozygous for the wild-type BRAF allele and harbouring mutually exclusive homozygous KRAS c. G34T (p. G12C) mutation (COSMIC Database, Forbes et al., 2011) as well as gastric cancer samples, which were obtained from fresh tumor tissue, collected intraoperatively or gastroscopically with patients' informed consent and approval from relevant Ethics Committee. Additionally, reference melanoma DNA samples with known mutation status were kindly provided by Dr. Ahmad Jalili (Division of Immunology, Medical University of Vienna). Two of them (MM1 and MM2) had wild-type genotypes and two (MM3 and MM4) were heterozygous for BRAF c. T1799A mutation.
Cell lines were cultured in Dulbecco's Modified Eagle's Medium (D6429, Sigma-Aldrich), supplemented with antibiotic-antimycotic solution (A5955, Sigma-Aldrich) and 10% fetal bovine serum at 37°C in an atmosphere enriched with 5% CO 2 at 95% relative humidity.
For comparison of the sensitivity of detection methods DNA from A375 and MIA PaCa-2 cell lines were mixed to create samples containing 50%, 20% and 2% of the A375 DNA. Furthermore, various DNA samples were diluted 10-, 100-and 1000-fold for the same purpose.
All samples are listed in Table 1 . DNA extraction from cancer samples and cell lines was performed using proteinase K and JETFLEX Genomic DNA Purification Kit (GENOMED). After extraction DNA was dissolved in water and quantified spectrophotometrically with NanoDrop 2000 (Thermo Scientific). Typically, DNA concentration varied between 100-500 ng/μl.
ARMS
The ARMS assay (Newton et al., 1989) , a simple PCRbased technique, utilizes a phenomenon of amplification arrest caused by non-complementary nucleotide(s) at 3' end of the primer. In this study we used a mutation-specific primer, resulting in formation of an additional product only in the presence of the c. A1799 allele. Three primers were used in a total concentration of 400 nM: one forward primer 5'-GCTTGCTCT-GATAGGAAAATGAG-3' and two reverse primers 5'-ACCCACTCCATCGAGATTTCT-3' (mutation specific) and 5'-CTGTGGATCACACCTGCCTTA-3' (control) at the concentrations of 133 nM, 173 nM and 93 nM, respectively. The 25 μl reaction mixture consisted of 1.25U HotStartTaq polymerase (Qiagen), 160 μM dNTPs (VWR), 1× Coral Load PCR Buffer (Qiagen), 1.5 mM MgCl 2 and from 100 ng to 500 ng of genomic DNA (the latter concentration for clinical samples). PCR was carried out for 40 cycles (40 s at 94°C, 40 s at 61°C, 40 s at 72°C), with initial denaturation for 15 min at 95°C and final extension for 5 min at 72°C, using Mastercycler Epigradient (Eppendorf), resulting in formation of one or two amplicons: 623 bp (control) and 134 bp (mutation). Results for all DNA samples were obtained in at least two independent experiments. DNA Electrophoresis. All PCR products were separated on 1-2% agarose gels (Sigma-Aldrich) stained with ethidium bromide (Fluka Analytical, Sigma Aldrich). Gel images were acquired with Alphaimager Mini (Protein Simple).
DNA Sequencing. DNA sequences were obtained in two PCR reactions, followed by sequencing in both directions on ABI 3730 automatic sequencer with capillary electrophoresis (Applied Biosystems). Two primers (Di Nicolantonio et al., 2008) , forward 5'-TGCTTGCTCTGATAG-GAAAATG-3' and reverse 5'-AGCATCTCAGGGC-CAAAAAT-3', were used for both amplifications.
Preparative PCR was carried out for 35 cycles (40 s at 94°C, 40 s at 58°C, 40 s at 72°C), with initial denaturation for 15 min at 95°C and final extension for 5 min at 72°C, resulting in formation of 228 bp product, using a 25 μl mixture of 1.25U HotStartTaq polymerase, 2 × 200 nM primers, 160 μM dNTPs, 1× PCR Buffer (Qiagen), 1.5 mM MgCl 2 and 100-500 ng of genomic DNA.
Subsequently, 10 µl of product was purified with Shrimp Alkaline Phosphatase (1U) and Exonuclease I (10U) (Fermentas) and reamplified with BigDye Terminator v3.1 Cycle Sequencing kit (Applied Biosystems) for 55 cycles (10 s at 95°C, 15 s at 50°C, 90 s at 60°C) with initial denaturation for 5 min at 95°C and final extension for 5 min at 60°C in a 10 μl mixture of 0.4 μl BigDye 3.1, 3.6 μl Sequencing Buffer, 0.002 nM primer (forward or reverse) and 2 μl product from the previous step.
Finally, products were purified on Centri-Sep CS-901 Columns with Sephadex (Princeton Separations) and processed for sequencing. All DNA sequences were obtained in at least two independent experiments.
Real-time PCR-based methods. Two detection methods, namely qPCR with hybridizing probes and High Resolution Melting (HRM) were carried out in LightCycler™ 480 instrument (Roche). All samples were amplified in a volume of 20 μl in duplicates in 96-well plates. Acquired data was analysed with LightCycler 480 Software (release 1.5.0.39 SP4). Real-time PCR with fluorescent hybridizing probes was performed with application of LightMix™ Kit BRAF V600E (TIB MOLBIOL), according to the manufacturer›s manual. Reaction components and cycling and melting parameters are provided in supplementary Table 1 and 2 (at www.actabp. pl). Sample mutation status was determined using the melting temperature analysis (Tm calling mode). For the HRM analysis LightCycler™ 480 High Resolution Melting Master Real-Time (Roche) was used in accordance with the manufacturer's manual. This method allows to detect point mutations by measuring the change of amplicon melting behaviour versus controls of known genotype. Since amplicon length has a crucial impact on the melting process, three different pairs of primers flanking the V600 codon were designed: forward 5'-TTCAT-GAAGACCTCACAGTAAAAA-3' and reverse 5'-CT-GATGGGACCCACTCCAT-3' for 77 bp amplicon, forward 5'-TCACAGTAAAAATAGGTGATTTTGG-3' and reverse 5'-CCACAAAATGGATCCAGACA-3' for 95 bp amplicon, forward 5'-GCACAGGGCATGGAT-TACTT-3' and reverse 5'-GATGACTTCTGGTGC-CATCC-3' for 195 bp amplicon. Reaction components as well as cycling and melting parameters are provided in supplementary Table 3 and 4 (at www.actabp.pl). Initial experiments allowed to establish the optimal MgCl 2 and DNA concentrations at 3 mM and 30 ng/reaction, respectively. Sample mutation status was determined using Gene scanning mode, with fluorescence level and temperature normalizations (normalization and temperature shift options) applied when necessary. Samples were clustered automatically and visual analysis was applied only to corroborate the results. Bioinformatic tools. Genomic sequence of BRAF was derived from NCBI database, accession number NG_007873.1. Primers were designed using primer3 (Rozen & Skaletsky, 2000) , primerBLAST (http://www. ncbi.nlm.nih.gov/tools/primer-blast/) and NetPrimer (http://www.premierbiosoft.com/netprimer/index. html). Collected DNA sequences were analysed with FinchTV 1.4.0 software (Geospiza, Inc.; Seattle, WA, USA; http://www.geospiza.com) and aligned in Jalview 2.6.1 (Clamp et al., 2004; Waterhouse et al., 2009 ) with MAFFT6 algorithm (Katoh et al., 2002; Katoh & Toh, 2008) . Sequences were processed with JustBio online tools (http://www.justbio.com) when needed.
RESULTS

ARMS
Initial experiments were designed to establish optimal conditions for ARMS. To ensure the formation of specific products, annealing temperature was set as high as possible, i.e. 61°C (Fig. 1A) , and total concentration of primers was lowered from initial 600 nM to 400 nM, in proportions of 1:0.7:1.3 (forward:reverse:mutation specific, respectively; initially 1:1:1) (Fig. 1B) , while the number of cycles was increased from initial 35 to 40, allowing for better sensitivity (Fig. 1C) .
After optimization of the ARMS assay we performed sensitivity tests using DNA isolated from cell lines and clinical melanoma samples with various c. A1799 allele content at 1-1000-fold dilutions. ARMS allowed us to detect the c. T1799A mutation in heterogeneous melanoma samples even at 1000-fold dilution, whereas minimal detectable c. A1799 allele content was at least 2%. Simultaneously, the results obtained from negative control samples excluded the possibility of false positive results (Fig. 2) . To evaluate ARMS usefulness as a diagnostic tool we performed mutation screening in a small group of gastric cancer samples, resulting in detection of the c. T1799A mutation in one of them (Fig. 3) . Arrows indicate positions of the expected products: control (upper -623 bp), mutation (lower -134 bp). Dilutions are specified below the gel images. Highest dilutions (1:1000) resulted in 0.1-0.5 ng of DNA per reaction.
DNA Sequencing
To determine the reliability of ARMS we sequenced DNA from both control cell lines and two gastric cancer samples, positive and negative for BRAF c. T1799A mutation, in both directions. In three cases sequencing data were consistent with ARMS results, while chromatogram of GC4 sample displayed a peak for the wild-type nucleotide only (Fig. 4A) .
We investigated this discrepancy by sequencing samples containing 50%, 20% and 2% of A375 DNA. The mutation was not detectable at the 2% level, thus showing lower sensitivity of sequencing compared to ARMS (Fig. 4B) .
Hybridizing probes. Application of hybridizing probes allowed for accurate BRAF c. T1799A mutation detection; we observed no false positive results among (A) C. T1799A mutation in GC4 sample is not detectable with sequencing -an adenine peak cannot be observed. (B) Sensitivity test of sequencing at various c. A1799 allele contents shows no c. T1799A mutation detection at 2% level, and a small adenine peak at 20% level.
the tested samples. The sensitivity of this method was similar to that of ARMS assay since it allowed for c. T1799A mutation detection in the GC4 sample, albeit its detection mechanism does not exclude the possibility of interpretation of low DNA quality samples as negative (there is no internal amplification control according to the manufacturer's information (Fig. 5) .
High Resolution Melting. Finally, we made an attempt to optimize and use the HRM method for c. T1799A mutation detection. We designed three pairs of primers flanking the p. 600 codon, amplifying products of different sizes. We could not obtain coherent and reproducible results for the 195 bp amplicon, thus the corresponding primer pair was excluded from further tests. The other two primer pairs allowed only to discriminate between homo-and heterozygous samples, C. T1799A mutation is detected in GC4 sample (3), thus suggesting detection sensitivity comparable to that of the ARMS assay. Samples negative for c. T1799A mutation (4-6) are clustered together with no template control (7). Sample description: 1, A375; 2, positive control DNA provided by manufacturer; 3, GC4, 4, GC3; 5, GC5; 6, GC6; 7, no template control. (A) and (B) HRM allows only to discriminate homo-and heterozygote, regardless of amplicon length (A, 77 bp; B, 95 bp). Wild-type MM samples are in the homozygotes group (blue curves), while heterozygous MM and 50% samples create a separate group (red curves). Melting curves were normalized and temperature-shifted. (C) Sensitivity test of HRM using the 95 bp amplicon. Samples must contain at least 20% of c. A1799 allele to be classified as heterozygotes (red curves) and therefore as mutated. Melting curves were normalized and temperature-shifted. Sample description: 1, A375; 2, MIA PaCa-2; 3, MM1; 4, MM2; 5, MM3; 6, MM4; 7, 50%; 8, 20%; 9, 2%.
since homozygous samples were clustered together, regardless of their mutation status (Fig. 6A and 6B ). The GC4 sample was classified to the homozygous sample group, despite the mutation detected by ARMS (Fig. 3 ) and hybridizing probes (Fig. 5) , therefore we decided to test the sensitivity of HRM with samples containing 50%, 20% and 2% of c. A1799 allele using the 95 bp amplicon primer pair. As expected, the 2% sample was clustered together with homozygotes, suggesting that HRM sensitivity was similar to that of sequencing (Fig. 6C) .
To conclude, HRM allowed only for discrimination of homo-and heterozygous samples, containing at least 20% of the c. A1799 allele. Upper c. A1799 allele content limit was not determined. A summary of the results is shown in Table 1 .
Sensitivity and specificity of mutation detection using ARMS and hybridizing probes
As the results of HRM analysis of BRAF c. T1799A mutation were unsatisfactory we decided to compare sensitivity and specificity of ARMS and hybridizing probes only and corroborate their results with Sanger sequencing. To achieve that goal we decided to scan 69 clinical samples obtained during gastric cancer resection with the above methods. Both ARMS and hybridizing probes allowed for detection of BRAF c. T1799A mutation in a single sample (GC4), (Table 2) . We observed no false positive or false negative results.
DISCUSSION
Determining BRAF mutation status is becoming a routine genetic procedure in cancer diagnostics. However, there is no widely accepted gold standard assay for BRAF mutation detection. The aim of our study was to compare different methods, including ARMS-PCR designed by us, for the detection of the BRAF c. T1799A mutation, which is the most common among BRAF tumour associated variants. Apart from the functional consequences, this phenomenon allows for application of various detection methods, with different sensitivity, costs, labour intensity or instrument requirements.
Our ARMS assay proved to be very sensitive, detecting the c. A1799 allele even at less than 2%. This is not surprising, as various amplification-based methods were shown to be highly sensitive in previous studies. Pyrophosphorolysis-activated polymerization, ARMS with fluorochrome labelling and nested allele-specific PCR allowed to detect the BRAF mutation even below the 1% level, although at the cost of more sophisticated reaction mechanisms (Yancovitz et al., 2007; Janssen et al., 2008; Maat et al., 2008; Ellison et al., 2010) . This is in contrast with the low sensitivity of Sanger sequencing demonstrated here or in previous studies (Yancovitz et al., 2007) , which requires from 20% to 30% of the mutant allele for its detection. Application of more sensitive methods allowed to discover BRAF mutations in uveal melanomas, initially described as negative (Janssen et al., 2008; Maat et al., 2008) , which raises a question whether some data assessing BRAF mutation frequency, obtained with sequencing, could have been underestimated.
While the c. T1799A (p. V600E) is a predominant BRAF polymorphism, rare tandem codon 600 mutations were found to have similar functional consequences Wan et al., 2004) . Our ARMS assay is presumably incapable of detecting most of them, including the p. V600E arising from c. TG1799-1800AA.
However, it can be used to detect the c. GT1798-1799AA/p. V600K tandem mutation. Rubinstein et al. (2010) suggested that p. V600K prevalence in melanoma was underestimated, reaching approximately 16.3% of all codon 600 mutations, and demonstrated clinical response to vemurafenib in a patient with an advanced, p. V600K-positive tumor.
One of the essential advantages of our ARMS assay is its simplicity. The qPCR-based ARMS method described by Ellison et al. (2010) displayed a similar sensitivity of 1% and possessed the ability to detect three different mutations (p. V600E, p. V600K and p. V600D). However, this methodology requires the use of a real-time thermocycler and six different oligonucleotides, including two pairs of primers and two fluorescent probes containing locked nucleic acid nucleotides, thereby considerably increasing the complexity of the reaction. It must be noted, however, that it also eliminates the need for gel electrophoresis, excludes the possibility of accidental contamination after the amplification and facilitates the assay's preparation, but at a considerably higher cost.
Additionally, ARMS versatility was proven by applying it to detect other gene mutations e.g. JAK2 c. G1849T (Chen et al., 2007) or NOTCH1 c. 7544-7545delCT (Rossi et al., 2012) . Real-time PCR-based ARMS technique has also been successfully implemented to detect N-RAS c.A182G or c.C181A mutations in melanoma (Ellison et al., 2010) .
We tried to utilize real-time PCR-based methods as an alternative for our ARMS assay. The first one, the LightMix hybridizing probe kit allowed us to confirm ARMS results, thus showing similar sensitivity, though the usefulness of the assay is doubtful because of the lack of an internal amplification control.
The overall performance of the second one, HRM assay was unsatisfactory in our experimental settings. Low sensitivity, combined with the inability to distinguish between homo-and heterozygous or mixed samples, in our opinion disqualifies this method from the BRAF mutation status testing. This was quite unexpected, as we have successfully employed HRM for point mutations in other genes (unpublished data), using the same instrument and reagents. A possible explanation is that the T > A transversion alters the homozygous amplicon's melting temperature insufficiently and only when heteroduplexes are formed, a significant change in melting behaviour can be observed. Herrmann et al. (2007) obtained similar results for HBB c. A20T mutation and demonstrated that discrimination can also be hampered by temperature variation across the plate, which limits the effective resolution of heat block instruments, including LC480 (Herrmann et al., 2007) . Although there is a possibility to detect homozygous variants by mixing wild-type and unknown DNA with HRM, so that any homozygous variant in the unknown sample will be detected as a heterozygote in the mixture, we decided not to utilize this method as it is more labor-intensive and may affect reproducibility of the results.
It is tempting to speculate on the rational level of desired detection sensitivity. If we consider testing pure, homo-or heterozygous samples, then every method tested here has sufficient sensitivity, with the exception of HRM for the discrimination of homozygotes. Given that tissue samples are often composed of various cells, including tumor infiltrating leukocytes, and the tumor itself can be highly heterogeneous (Gerlinger et al., 2012) , it might be more informative to detect even the smallest amounts of mutated DNA, as it was demonstrated here and in other studies. While this approach may re-sult in detection of "passenger" mutations, even a low number of cancer cells harbouring BRAF mutant alleles can be selected during progression of the disease (Lin et al., 2011) .
In summary our results show that simple ARMS is a highly sensitive and cost effective method for BRAF mutational screening (Table 1) . Comparing real-time PCR based methods hybridizing probe-based detection seems to be more effective than the HRM assay. Limitations of our study include the number of samples tested and detection of only the most common BRAF mutation.
